Health ❯ Healthcare ❯ Pharmaceuticals

Clinical Trials

Drug Development Weight Loss Drugs Drug Efficacy Cancer Treatments Drug Safety Alzheimer's Disease Phase 3 Trials Cancer Treatment Obesity Treatment Gene Therapy

Regeneron Shares Sink 11% After Melanoma Combo Fails Against Keytruda in Phase 3

The miss forces investors to rethink Regeneron’s near-term growth path.

Apnimed’s Pill Cuts Sleep Apnea Events in Phase 3 as FDA Filing Advances

ImmunityBio Investors Face May 26 Lead-Plaintiff Deadline in Securities Suit Tied to FDA Anktiva Rebuke

Novo Nordisk’s Wegovy Pill Shows Strong Results, Reinforcing Stock Rebound

Altimmune Targets Second-Half 2026 Launch for Global Phase 3 MASH Trial

Axsome Reports 57% Q1 Sales Jump as FDA Clears Auvelity for Alzheimer’s Agitation

Nektar Investors Face May 5 Deadline in Securities Suit Over REZOLVE-AA Trial Claims

FDA Panel Rejects AstraZeneca Breast Cancer Drug, Backs Prostate Therapy

Sagimet Prices $175 Million Stock Offering as It Plans U.S. Phase 3 Acne Trial

Novo Nordisk’s Oral Semaglutide Lowers HbA1c in Teens in Pivotal Trial

EU Drug Panel Backs Sanofi’s Cenrifki for Non‑Relapsing SPMS

AstraZeneca’s Tozorakimab Hits Phase III Goal in COPD, Marking Third Positive Pivotal Trial

Xenon Presents Phase 3 Azetukalner Results and 48‑Month Data at American Academy of Neurology Meeting

ImmunityBio Investors Face May 26 Deadline to Seek Lead Role in Securities Case

Lilly’s Oral Foundayo Matches Insulin on Heart Safety in Major Diabetes Trial

Germany Rules No Added Benefit for New Alzheimer Antibodies After Major Review Finds Little Effect

FDA Orders Post-Approval Safety Studies for Lilly’s Foundayo Weight-Loss Pill

Traws Pharma Raises $10 Million in PIPE With Up to $60 Million Tied to Trial Milestones

Spyre Drug Meets Midstage Target in Ulcerative Colitis, Stock Rallies

Law Firms Urge Nektar Investors to Seek Lead Role in Securities Suit Over REZOLVE-AA Protocol Claims